Aug 21, 2015 waldenstrom macroglobulinemia is a rare disease with an incidence of 3 cases per million people per year in the us. Phase 12 dose escalation study in patients with relapsed or refractory waldenstrom s macroglobulinemia rochester, mn. Waldenstrom macroglobulinemia wm, or lymphoplasmacytic lymphoma, is a type of slowgrowing nonhodgkins lymphoma with an annual incidence of 3. Bcells normally mature into plasma cells whose job is to produce immunoglobulins antibodies to help the body fight infections. Kastritis e, gavriatopoulou m, kyrtsonis mc, et al. Wm is considered to be an indolent slow growing lymphoma and it is primarily found in the bone marrow although lymph nodes. Waldenstroms macroglobulinemia has a unique mutational profile. Full text new developments in the management of waldenstrom. Serum free light chains are commonly altered and may be more useful to follow patients that developed light chain al amyloidosis. The genomic landscape of waldenstrom macroglobulinemia is characterized by highly recurring myd88 and whimlike cxcr4 mutations, and small somatic deletions associated with bcell lymphomagenesis. May 28, 2019 symptoms attributable to waldenstroms macroglobulinemia wm reconfirmation of the complete response status is required by repeat immunofixation studies very good partial response. Although wm remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in t. Presence of igm monoclonal protein associated with. Phase 3 trial of ibrutinib plus rituximab in waldenstrom.
What is the pathophysiology of waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia wm is a clinical syndrome that is defined as. Waldenstroms macroglobulinemia wm is a lymphoproliferative disease of b. Waldenstroms macroglobulinemia front line treatment. Sdf1cxcr4 and vla4 interaction regulates homing in waldenstrom macroglobulinemia. Wm is a malignant lymphoplasmoproliferative disorder with monoclonal pentameric igm production. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Waldenstrom macroglobulinemia clinical trials mayo. San miguel1,2 abstract little is known about the dna cell content and cell cycle characteristics of immunoglobulin ig m monoclonal gammopathies. Waldenstrom macroglobulinemia fact sheet spanish pdf. Lymphoplasmacytic lymphomawaldenstrom macroglobulinemia. Bortezomib, fludarabine, thalidomide, everolimus, ibrutinib, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in relapsed wm.
Very good partial response rate or better, progressionfree su. Waldenstrom macroglobulinemia genetic and rare diseases. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Waldenstroms macroglobulinemia definition of waldenstroms macroglobulinemia by the free dictionary. Waldenstroms macroglobulinemia the free dictionary. Longterm followup of ibrutinib monotherapy in symptomatic. Waldenstrom macroglobulinemia treatment algorithm 2018 blood. Ghobrial1 disease assessment in waldenstrom macroglobulinemia wm is dependent. How i treat waldenstrom macroglobulinemia blood american. Waldenstrom macroglobulinemia wm is a lowgrade incurable immunoglobulin m. Regarding epidemiology, per the 2016 registry data by the japanese society of hematology, wm and lymphoplasmacytic lymphoma lpl cases were 229 and 125, respectively 1. Each protein made by the wm cells is the same, so it is called a monoclonal protein, or just an m protein. The immunoglobulin free light chain assay, which is quite valuable in myeloma, has not been well established in wm.
Original contribution cell cycle analysis of waldenstroms macroglobulinemia enrique m. Brutontyrosinekinaseinhibitorsinwaldenstrom macroglobulinemia. Does ibrutinib produce longterm responses in previously treated waldenstrom macroglobulinemia wm, and. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the igm monoclonal protein and those that have symptoms related to progressive marrow and nodal. Pdf waldenstroms macroglobulinemia wm is a lymphoproliferative disease of b. The diagnosis of wm is established by the presence of lymphoplasmacytic lymphoma in the bone marrow or other organs, a monoclonal igm paraproteinemia and the recurrent myd88. The most common known genetic change associated with this condition is a mutation in the myd88 gene, which is found in more than 90 percent of affected individuals. Waldenstrom macroglob ulinemialymphoplasmacytic lymphoma. Waldenstroms macroglobulinemia an overview sciencedirect. Sep 14, 2020 itzykson r, le garfftavernier m, katsahian s, et al. Overview on clinical trials in waldenstroms macroglobulinemia clinical trial outcomes intermittent chlorambucil administration 0. Waldenstrom s macroglobulinemia wm fact sheet pdf overview of waldenstrom s macroglobulinemia wm waldenstrom s macroglobulinemia wm is a rare subtype of bcell lymphoma, making up 1 to 2 percent of all nonhodgkin lymphoma nhl cases. The cancer cells make large amounts of an abnormal protein called amacroglobulin.
The cancer cells make large amounts of an abnormal protein called a macroglobulin. Knowledge generated the median progression free survival in previously treated patients with wm exceeded 5 years and was affected by both myd88 and cxcr4 mutation status. Wm cells have features of both blymphocytes and plasma cells lymphoplasmacytic. Oct 01, 20 waldenstrom macroglobulinemia is a chronic, slowgrowing lymphoproliferative disorder. Acalabrutinib monotherapy in patients with waldenstrom. Castillo,1 claudia pabaprada,1 steven treon,1 robert redd,3 edie weller,3 and irene m. Recently, many new drugs have been developed for the treatment of waldenstrom macroglobulinemia wm. This results in roughly 1,000 to 1,500 new diagnoses each year. The buildup of this m protein in the body can lead to many of the. Treatment and prognosis of waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia wm is a rare lymphoplasmacytic lymphoma.
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of waldenstrom macroglobulinemia. Given wms natural history, reduction of therapy toxicity is an important part of treatment selection. New recommendations are given regarding the role of myd88 l265p detection in the diagnosis of wm and the role of ibrutinib in the treatment of symptomatic wm. Research article a jh extramedullary waldenstr om macroglobulinemia ranjit banwait,1 yosra aljawai,1 joseph cappuccio,1 serena mcdiarmid,1 elizabeth a. This condition used to be called waldenstrom s macroglobulinemia, so some people refer to it as waldenstrom s. Waldenstrom macroglobulinemia wm is a slowgrowing, rare type of nonhodgkin lymphoma, which is a blood cancer. Waldenstrom macroglobulinemia wm is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a nonhodgkin lymphoma, and igm monoclonal gammopathy. With a median followup of 59 months, no unexpected toxicities were encountered, and the incidence of atrial. Feb 01, 2021 assessment of bone marrow response in waldenstrom s macroglobulinemia. Disease overview waldenstrom macroglobulinemia wm is a lymphoplasmacytic. Waldenstrom macroglobulinemia wm is a type of nonhodgkin lymphoma nhl that produces large amounts of an abnormal protein called.
Among patients with igm mgus, the presence of two adverse risk factors abnormal serum free light chain ratio and a serum monoclonal protein. Waldenstroms macroglobulinemia wm lymphoma australia. Waldenstrom macroglobulinemia wm is an uncommon lymphoma. To optimize the treatment according to the prognosis and to facilitate the comparison of trials, we developed an international prognostic scoring system for wm in a series of 587 patients with clearly defined criteria for diagnosis and for initiation of treatment. Jacksonville, fl recent reports have identified a specific oncogenic mutation l265p of the myd88 gene in approximately 90% of the patients with waldenstroms macroglobulinemia. Instead, its found when the person has blood tests done for some other reason. The major risk factors are male gender, caucasian race, and age over 60 4. Similarly to other indolent lymphomas, asymptomatic patients should not receive treatment as there are no data to support early initiation of therapy over a. Ibrutinib monotherapy in symptomatic, treatmentnave patients with waldenstrom macroglobulinemia. Serum immunoglobulin free light chain correlates with tumor.
Waldenstrom macroglobulinemia wm is a cancer of the. Serum free light chain elevation is associated with a shorter time to treatment in waldenstrom s macroglobulinemia. Although wm remains to be an incurable disease with a heterogeneous clinical course, the. Sometimes, waldenstrom macroglobulinemia wm isnt causing any symptoms when its first found. Jan 17, 2017 the involved serum free light chain is a useful marker of tumor burden and acts as a leading indicator of response and progression before the intact igm, presumably because of its shorter half. As time to response can take months, chlorambucil is not an appropriate option for patients needing a rapid disease control. International prognostic scoring system for waldenstrom. Wm is a type of cancer affecting two types of b cells. Waldenstrom macroglobulinemia wm is a rare lowgrade bcell lymphoma. A clonal disease of b lymphocytes, waldenstrom macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the. It usually affects older adults and is primarily found in the bone. Waldenstrom s macroglobulinemia wm treatment options, considering the disease rarity, have been derived from phase ii study data with the exception of a few phase iii clinical trials. Pdf waldenstrom macroglobulinemia is a rare lymphoproliferative. Pdf extramedullary waldenstrom macroglobulinemia jorge.
Waldenstrom macroglobulinemia wm is a lymphoproliferative disorder. The treatment options for waldenstrom macroglobulinaemia. The 2018 esmo clinical practice guidelines on waldenstroms macroglobulinemia wm are based on results from recent studies and updated analyses. A sursyvlwr gh xq fdvr luis g ramonrodriguez, gelquin musteliercelza, onel avilacabrera, leslie gonzalezpinedo, adys gutierrezdiaz, carlos hernandez. Waldenstrom macroglobulinemia wm is a distinct clinicopathologic. Fundoscopic abnormalities are seen in approximately 3040% of patients with wm.
The most consistent feature of the bone marrow or lymph nodes of patients with wm is the presence of pleomorphic blineage cells at different stages of maturation, such as small lymphocytes, lymphoplasmacytoid cells abundant basophilic cytoplasm but lymphocytelike nuclei, and plasma cells. The immunoglobulin free light chain assay, which is quite valuable in. Waldenstrom macroglobulinemia early detection, diagnosis. Deletion 17p del 17p was initially reported at a low frequency in. Signs and symptoms of waldenstrom macroglobulinemia. The most consistent feature of the bone marrow or lymph nodes of patients with wm is the presence of pleomorphic blineage cells at different stages of maturation, such as small lymphocytes, lymphoplasmacytoid cells abundant basophilic cytoplasm but lymphocytelike nuclei, and plasma. Waldenstrom macroglobulinemia clinical trials mayo clinic. What is new in the treatment of waldenstrom macroglobulinemia. Waldenstroms macroglobulinemia wm is a rare, incurable hematologic disorder with a relatively. Waldenstrom macroglobulinemia diagnosis and treatment. Mar 30, 2016 if you have problems viewing pdf files, download the latest version of adobe reader for language access assistance, contact the ncats public information officer genetic and rare diseases information center gard po box 8126, gaithersburg, md 208988126 toll free.
Waldenstrom macroglobulinemia wm is a lowgrade bcell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin m. Waldenstrom macroglobulinemia wm is a type ofnonhodgkin lymphoma1nhl. Waldenstrom macroglobulinemia symptoms and causes mayo clinic. Consensus treatment recommendations from the tenth international.
Updates in prognostication and treatment of waldenstroms. Wm is a rare, indolent lymphoma with lymphoplasmacytic infiltration of the bone marrow bm and monoclonal. Waldenstrom macroglobulinemia wm is a rare type of nonhodgkin lymphoma. Update of the phase ii study on drc in first line treatment. Waldenstrom macroglobulinemia wm is a rare lymphoproliferative disorder characterized by the presence of monoclonal immunoglobulin m in serum. Balancing risk versus benefit in the treatment of waldenstrom s macroglobulinemia patients with nucleoside analoguebased therapy. Further studies are needed to establish its efficacy against current standard treatments and to investigate whether outcomes can be improved with combination therapies. Wm found this way is sometimes called asymptomatic or smoldering wm. Serum immunoglobulin free light chain correlates with tumor burden markers in waldenstrom macroglobulinemia. It occurs in a type of white blood cell called a blymphocyte or bcell. Overview on clinical trials in waldenstroms macroglobulinemia. Jul 19, 2018 waldenstrom macroglobulinemia wm is a type of nonhodgkin lymphoma nhl. The median progression free survival in previously treated patients with wm exceeded 5 years and was affected by both myd88 and cxcr4 mutation status.
This study provides evidence that acalabrutinib is active as singleagent therapy with a manageable safety profile in patients with treatmentnaive, or relapse or refractory waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia blood american society of. Pdf cell cycle analysis of waldenstroms macroglobulinemia. Waldenstrom s macroglobulinemia wm wednesday, april 21, 2021 12. Epidemiology, pathogenesis, clinical manifestations, and. Oct 17, 2018 since macroglobulinemia cells highly express bcl.
877 889 297 346 305 1434 1412 282 846 771 1186 1216 339 410 1542 1466 339 513 35 1478